Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 19, 2023 08:30 ET | Source: Longeveron

Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal

-- Full results published in European Heart Journal Open -- -- Study met primary safety endpoint -- -- All patients alive, transplant-free, and maintained expected rate of growth one year...
January 06, 2023 09:58 ET | Source: Longeveron

UPDATE -- Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones

– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 – – Extended cash runway into 2H24 – MIAMI, Jan. 06, 2023 (GLOBE NEWSWIRE) --...
January 06, 2023 08:30 ET | Source: Longeveron

Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones

– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 – – Extended cash runway into 2H24 – MIAMI, Jan. 06, 2023 (GLOBE NEWSWIRE) --...
November 29, 2022 16:30 ET | Source: Longeveron

Longeveron to Participate in Upcoming 2022 Investor Conferences

MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs,...
November 14, 2022 08:00 ET | Source: Longeveron

Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results

-- Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron’s Phase 2a trial for Alzheimer’s Disease -- -- Conference call...
November 10, 2022 08:30 ET | Source: Longeveron

Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’s Disease

MIAMI, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs,...
November 07, 2022 09:06 ET | Source: Longeveron

Longeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022

MIAMI, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs,...
October 05, 2022 08:30 ET | Source: Longeveron

Longeveron to Present at the Annual Dawson James Small Cap Growth Conference

MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs,...
September 15, 2022 08:30 ET | Source: Longeveron

Longeveron Names Jerome Bailey Vice President of Business Operations

MIAMI, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it has...
September 06, 2022 08:30 ET | Source: Longeveron

Longeveron to Present at H.C. Wainwright 24th Annual Global Investment Conference

MIAMI, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...